Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). The main questions it aims to answer are:
* Is ER-100 safe when given as a single dose to people with OAG or NAION
* What side effects may occur, if any, after taking ER-100?
Participants will:
* Receive a single dose of ER-100
* Undergo safety assessments including detailed eye examination and laboratory tests
* Provide body fluid samples (tears, saliva, feces, urine) to help researchers understand how the drug is processed and cleared from the body
* Complete questionnaires about their quality of life
* Be followed for up to 5 years to monitor long-term health and vision outcomes
Gender: All
Ages: 40 Years - 85 Years
Open Angle Glaucoma (OAG)
NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)